|
🐢
|
Diagnosis and Management of Multiple Myeloma: A Review.
9 auth.
A. Cowan,
D. Green,
M. Kwok,
Sarah S. Lee,
D. Coffey,
L. Holmberg,
...
S. Tuazon,
A. Gopal,
E. Libby
|
9 |
2022 |
9
🐢
|
|
🐜
|
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
38 auth.
S. Lonial,
Hans C. Lee,
A. Badros,
S. Trudel,
A. Nooka,
A. Chari,
Al-Ola Abdallah,
N. Callander,
N. Lendvai,
D. Sborov,
A. Suvannasankha,
K. Weisel,
L. Karlin,
E. Libby,
B. Arnulf,
...
T. Facon,
C. Hulin,
K. Kortüm,
P. Rodríguez-Otero,
S. Usmani,
P. Hari,
R. Baz,
H. Quach,
P. Moreau,
P. Voorhees,
I. Gupta,
A. Hoos,
E. Zhi,
January Baron,
T. Piontek,
E. Lewis,
R. Jewell,
E. Dettman,
R. Popat,
S. Esposti,
J. Opalinska,
P. Richardson,
A. Cohen
|
9 |
2019 |
9
🐜
|
|
🐜
|
Global Burden of Multiple Myeloma
34 auth.
A. Cowan,
Christine Allen,
A. Barać,
H. Basaleem,
I. Benseñor,
M. Curado,
Kyle Foreman,
Rahul Gupta,
James D. Harvey,
H. Hosgood,
Mihajlo Jakovljevic,
M. Jakovljevic,
Y. Khader,
S. Linn,
D. Lad,
...
L. Mantovani,
V. M. Nong,
A. Mokdad,
M. Naghavi,
M. Postma,
G. Roshandel,
G. Roshandel,
K. Shackelford,
M. Sisay,
C. Nguyen,
T. Tran,
B. Xuan,
B. Xuan,
B. Xuan,
K. Ukwaja,
S. Vollset,
E. Weiderpass,
E. Libby,
C. Fitzmaurice
|
8 |
2018 |
8
🐜
|
|
🐜
|
A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY.
33 auth.
C. Tam,
Stephen Samuel Opat,
S. D’Sa,
W. Jurczak,
Hui-Peng Lee,
G. Cull,
R. Owen,
P. Marlton,
B. Wahlin,
R. G. Sanz,
H. McCarthy,
S. Mulligan,
A. Tedeschi,
J. Castillo,
J. Czyż,
...
C. Fernández de Larrea,
D. Belada,
E. Libby,
J. Matous,
M. Motta,
T. Siddiqi,
M. Tani,
M. Trněný,
M. Minnema,
C. Buske,
V. Leblond,
J. Trotman,
W. Chan,
J. Schneider,
S. Ro,
A. Cohen,
Jane E. Huang,
M. Dimopoulos
|
8 |
2020 |
8
🐜
|
|
🐬
|
Global burden of multiple myeloma: A systematic analysis for the Global Burden of Disease study 2016.
A. Cowan,
E. Libby,
C. Fitzmaurice
|
8 |
2018 |
8
🐬
|
|
🐜
|
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
50 auth.
E. Kastritis,
G. Palladini,
M. Minnema,
A. Wechalekar,
A. Jaccard,
Hans C. Lee,
V. Sanchorawala,
S. Gibbs,
P. Mollee,
C. Venner,
Jin-Hai Lu,
S. Schönland,
M. Gatt,
Kenshi Suzuki,
Kihyun Kim,
...
M. Cibeira,
M. Beksaç,
E. Libby,
J. Valent,
V. Hungria,
S. Wong,
M. Rosenzweig,
N. Bumma,
A. Huart,
M. Dimopoulos,
D. Bhutani,
A. Waxman,
S. Goodman,
J. Zonder,
Selay Lam,
K. Song,
T. Hansen,
S. Manier,
W. Roeloffzen,
K. Jamroziak,
F. Kwok,
C. Shimazaki,
Jin-Seok Kim,
E. Crusoé,
T. Ahmadi,
N. Tran,
X. Qin,
S. Vasey,
B. Tromp,
J. Schecter,
B. Weiss,
S. Zhuang,
J. Vermeulen,
G. Merlini,
R. Comenzo
|
8 |
2021 |
8
🐜
|
|
🐜
|
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
34 auth.
F. Morschhauser,
N. Fowler,
P. Feugier,
R. Bouabdallah,
H. Tilly,
L. Palomba,
C. Fruchart,
E. Libby,
R. Casasnovas,
I. Flinn,
C. Haioun,
H. Maisonneuve,
L. Ysebaert,
N. Bartlett,
K. Bouabdallah,
...
P. Brice,
V. Ribrag,
N. Daguindau,
S. le Gouill,
G. Pica,
A. M. García-Sancho,
A. López-Guillermo,
J. Larouche,
K. Ando,
M. G. da Silva,
M. André,
P. Zachée,
L. Sehn,
K. Tobinai,
G. Cartron,
David R. Liu,
Jianming Wang,
L. Xerri,
G. Salles
|
8 |
2018 |
8
🐜
|
|
🐜
|
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
56 auth.
P. Richardson,
S. Jacobus,
E. Weller,
H. Hassoun,
S. Lonial,
N. Raje,
E. Medvedova,
P. McCarthy,
E. Libby,
P. Voorhees,
R. Orlowski,
L. Anderson,
J. Zonder,
C. Milner,
C. Gasparetto,
...
M. Agha,
A. Khan,
D. Hurd,
K. Gowin,
R. Kamble,
S. Jagannath,
N. Nathwani,
M. Alsina,
R. Cornell,
Hamza Hashmi,
E. Campagnaro,
Astrid C. M. Andreescu,
T. Gentile,
M. Liedtke,
Kelly Godby,
A. Cohen,
T. Openshaw,
M. Pasquini,
S. Giralt,
J. Kaufman,
A. Yee,
E. Scott,
P. Torka,
A. Foley,
M. Fulciniti,
K. Hebert,
M. Samur,
Kelly Masone,
Michelle E. Maglio,
Andrea A. Zeytoonjian,
Omar Nadeem,
R. Schlossman,
J. Laubach,
Claudia E. Paba-Prada,
I. Ghobrial,
A. Perrot,
P. Moreau,
H. Avet-Loiseau,
M. Attal,
K. Anderson,
N. Munshi
|
7 |
2022 |
7
🐜
|
|
🐜
|
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
17 auth.
S. Trudel,
N. Lendvai,
R. Popat,
P. Voorhees,
B. Reeves,
E. Libby,
P. Richardson,
L. Anderson,
H. Sutherland,
K. Yong,
...
A. Hoos,
M. Gorczyca,
S. Lahiri,
Zangdong He,
D. Austin,
J. Opalinska,
A. Cohen
|
7 |
2018 |
7
🐜
|
|
🐜
|
Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
13 auth.
S. Trudel,
N. Lendvai,
R. Popat,
P. Voorhees,
B. Reeves,
E. Libby,
P. Richardson,
A. Hoos,
I. Gupta,
V. Bragulat,
...
Zangdong He,
J. Opalinska,
A. Cohen
|
7 |
2019 |
7
🐜
|
|
🐜
|
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
16 auth.
A. Yee,
W. Bensinger,
J. Supko,
P. Voorhees,
J. Berdeja,
P. Richardson,
E. Libby,
Ellen E. Wallace,
Nicole E Birrer,
Jill N. Burke,
...
D. Tamang,
Min Yang,
Simon S. Jones,
C. Wheeler,
R. Markelewicz,
N. Raje
|
7 |
2016 |
7
🐜
|
